Levodopa: Clinical Trials

16 trials of Levodopa, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed. 16 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 316Completed 16
Phase 23Completed 3

Follow Levodopa: new trials by email Literature Review of Levodopa trials Research Report on Levodopa

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
HRG2010; Sustained-release Carbidopa/Levodopa administered placebo, Sustained-release Carbidopa/Levodopa; HRG2010 placebo - Parkinson's Disease
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.1652024-11-062026-06-08
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD) - Parkinson's Disease (PD)
Phase 3CompletedAbbVie1742020-10-192022-11-18
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease
PR Oxycodone, Levodopa, Oxycodone Placebo - Parkinson Disease
Phase 2 / Phase 3CompletedUniversity Hospital, Toulouse672016-09-012026-05-04
Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke
Levodopa, Virtual Reality based therapy - Ischaemic Stroke
Phase 3CompletedSingapore General Hospital92014-01-012017-02-10
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
Rotigotine, Placebo Patch, L-dopa - Idiopathic Parkinson's Disease
Phase 3CompletedUCB Pharma3462012-07-012018-04-04
Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease
duloxetine, placebo of duloxetine, injection of apomorphine - Parkinson's Disease
Phase 3CompletedUniversity Hospital, Toulouse282011-05-012017-02-23
Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa) - Parkinson's Disease
Phase 2 / Phase 3CompletedBiotie Therapies Inc.4202011-03-012019-01-17
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
BIA 9-1067, Entacapone, Placebo - Parkinson's Disease
Phase 3CompletedBial - Portela C S.A.6002011-03-012015-09-18
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
BIA 9-1067, Placebo, Levodopa - Parkinson's Disease
Phase 3CompletedBial - Portela C S.A.4272011-03-012015-10-19
A Trial of Levodopa in Angelman Syndrome
Levodopa, Placebo Oral Capsule - Angelman Syndrome
Phase 2 / Phase 3CompletedWen-Hann Tan672011-01-012020-07-15
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
Levodopa (Pardoprunox), Placebo Comparator - Advanced Stage Parkinson's Disease
Phase 3CompletedSolvay Pharmaceuticals2952007-03-012015-02-27
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) - Parkinson's Disease
Phase 3CompletedNovartis4932005-08-012017-05-17
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease
Phase 3CompletedNovartis Pharmaceuticals7472004-09-012012-04-23
Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome
pramipexole, levodopa in combination with benserazide - Restless Legs Syndrome
Phase 3CompletedBoehringer Ingelheim582003-02-012013-11-01
A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS
cabergoline, levodopa - Restless Legs Syndrome
Phase 3CompletedPfizer3612003-01-012008-10-29
Timing of Levodopa Treatment in Parkinson's Disease
levodopa - Parkinson's Disease
Phase 3CompletedNational Institute of Neurological Disorders and Stroke (NINDS)1998-01-012005-06-24

Conditions studied

Parkinson Disease (12)  ·  Dyskinesias (2)  ·  Restless Legs Syndrome (2)  ·  Angelman Syndrome (1)  ·  Ischemic Stroke (1)  ·  Stroke (1)  ·  Tremor (1)

Sponsors

Bial - Portela C S.A. (2)  ·  University Hospital, Toulouse (2)  ·  AbbVie (1)  ·  Biotie Therapies Inc. (1)  ·  Boehringer Ingelheim (1)  ·  Jiangsu HengRui Medicine Co., Ltd. (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  Novartis (1)  ·  Novartis Pharmaceuticals (1)  ·  Pfizer (1)  ·  Singapore General Hospital (1)  ·  Solvay Pharmaceuticals (1)  ·  UCB Pharma (1)  ·  Wen-Hann Tan (1)

Countries

United States (7)  ·  Canada (4)  ·  France (3)  ·  Portugal (3)  ·  Switzerland (3)  ·  Argentina (2)  ·  Austria (2)  ·  Chile (2)  ·  China (2)  ·  Germany (2)  ·  Italy (2)  ·  Sweden (2)  ·  Turkey (Türkiye) (2)  ·  Ukraine (2)  ·  Australia (1)

Top investigators

Ann Neale, RN (1)  ·  Anne Slavotinek, MD (1)  ·  Carlos A. Bacino, MD (1)  ·  Cary Fu, MD (1)  ·  Christine Brefel-Courbon, MD (1)  ·  Joaquim Ferreira, MD, PhD (1)  ·  Logan Wink, M.D (1)  ·  Lynne M. Bird, MD (1)  ·  Stanley Fahn (1)

Results publications

PMID 19058133, PMID 20582993, PMID 21060282, PMID 22101745, PMID 22316635, PMID 25008546, PMID 26725544, PMID 28027332, PMID 28827011, PMID 35148289, PMID 36402160, PMID 38850081, PMID 40979212, PMID 41045349, PMID 41324738

NIH funding

2019 (1)